MedPath

Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty.

Not Applicable
Conditions
Osteoarthritis of hip joint
Registration Number
JPRN-UMIN000027501
Lead Sponsor
Yokohama City University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
90
Inclusion Criteria

Not provided

Exclusion Criteria

(a) a history of disorder(s) that might affect bone or mineral metabolism, (b) gastrointestinal disease, (c) renal dysfunction, (d) taking any agents for osteoporosis, (e) taking corticosteroids, and (f) perioperative fracture of femur that required additional fixation using plates and wires.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Periprosthetic bone mineral density measured by dual-energy X-ray(Postoperative 1-year, 2-year, 8 to 9-year)
Secondary Outcome Measures
NameTimeMethod
Occurrence of aseptic loosening and periprsthetic fracture
© Copyright 2025. All Rights Reserved by MedPath